ArticleMicrobiology spectrum2026
Synergistic effects of ceftriaxone combined with BLI-489 against NDM-producing
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Octadecyl 3-(3, 5-di-tert-butyl-4-hydroxyphenyl) propanoate nanosponges: enhanced antibacterial and antibiofilm activity against multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The New Delhi metallo-β-lactamase-producing IMPORTANCE: The global spread of NDM-Kp poses a major challenge to healthcare systems because of the scarcity of effective treatment options. In response to the urgent need for new therapeutic strategies, this study explores the CRO/BLI-489 as a promising alternative for overcoming MBL-mediated resistance. Although not yet an established therapy, this approach demonstrates the potential to restore cephalosporin efficacy, inhibit biofilm formation, and reduce cytotoxicity. These results offer valuable insights that may guide the development of future treatments for infections caused by multidrug-resistant pathogens. Our findings underscore the importance of further preclinical and clinical studies to validate this strategy and contribute to the global effort against antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.